Lemaitre Vascular (LMAT) Liabilities and Shareholders Equity (2010 - 2026)

Lemaitre Vascular (LMAT) has reported Liabilities and Shareholders Equity for 17 consecutive years, with $629.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 13.22% year-over-year to $629.5 million; the TTM figure through Mar 2026 stood at $2.4 billion (up 31.0% YoY), while the FY2025 annual figure was $615.7 million, up 11.58% from the prior year.
• Liabilities and Shareholders Equity grew to $629.5 million in Q1 2026 per LMAT's latest filing, from $615.7 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $629.5 million in Q1 2026 and bottomed at $292.5 million in Q1 2022.
• Historically, Liabilities and Shareholders Equity has averaged $420.5 million across 5 years, with a median of $354.0 million in 2024.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity increased 4.34% — and 2024, when it jumped 59.13%.
• Lemaitre Vascular's Liabilities and Shareholders Equity stood at $310.5 million in 2022, then climbed by 11.69% to $346.8 million in 2023, then surged by 59.13% to $551.8 million in 2024, then advanced by 11.58% to $615.7 million in 2025, then advanced by 2.25% to $629.5 million in 2026.
• Business Quant data shows LMAT's Liabilities and Shareholders Equity at $629.5 million in Q1 2026, $615.7 million in Q4 2025, and $598.1 million in Q3 2025.